Wegovy is the FDA-approved branded version of semaglutide for weight loss, manufactured by Novo Nordisk. Both Hims and Ro can prescribe Wegovy through their weight loss programs and coordinate delivery via partner pharmacies. The medication itself is the same — Novo Nordisk’s manufacturer-set pricing applies regardless of which platform writes the prescription. The differences between Hims and Ro for Wegovy specifically come down to program fees, insurance navigation, and the wraparound clinical experience. This wegovy hims vs ro comparison breaks down 2026 costs, eligibility screening, and delivery logistics. The summary: medication cost is set by Novo Nordisk and similar at both platforms; program fees and clinical experience are the actual variables.
Wegovy pricing — set by Novo Nordisk
Wegovy’s list price is approximately $1,349 per month (28-day supply) at Novo Nordisk’s manufacturer pricing. With insurance covering Wegovy for FDA-approved indications, patient cost depends on plan formulary, prior authorization status, and copay structure — typically $25-150/month for covered patients.
Without insurance, the list price applies but Novo Nordisk’s Wegovy savings program can reduce the cost for eligible patients. Self-pay patients without insurance can sometimes access Wegovy for around $499/month through Novo Nordisk’s NovoCare Pharmacy direct-to-patient channel, though eligibility is limited.
This pricing applies regardless of whether the prescription is written through Hims, Ro, a primary care doctor, or a bariatric medicine specialist. The platform doesn’t change the medication’s underlying cost.
Hims vs Ro program fees on top of Wegovy
Beyond the medication cost, each platform adds program fees:
Hims weight loss:
- Initial visit: $79
- Monthly cost for ongoing care: $99-199 (varies by plan)
- Promotional pricing often available at signup
Ro Body weight loss:
- Initial visit: $99
- Monthly membership: $145
- Includes clinician access, lab work review, ongoing prescription management
For Wegovy patients, the program fee is added on top of the $1,349/month list price (or whatever discounted price applies). Total monthly cost for a Wegovy patient through Hims is typically $1,448-1,548; through Ro it’s typically $1,494. The difference is small relative to medication cost. See our individual Hims review and Ro review.
Eligibility screening — both follow FDA labeling
Both platforms screen for Wegovy eligibility per FDA labeling: BMI 27+ with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, sleep apnea, etc.) or BMI 30+ without comorbidities. Patients must be 12+ years old. Adolescents 12-17 require a separate clinical pathway.
Contraindications screened at both platforms include:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy or planning pregnancy in next 2 months
- Severe gastrointestinal disease including gastroparesis
- Severe renal or hepatic impairment
The screening is appropriately conservative at both platforms. Patients with contraindications are screened out and may be offered alternative medications where appropriate.
Insurance coordination — broadly similar at both
Neither Hims nor Ro bills insurance for the visit or program fee. Both coordinate Wegovy prescriptions with patient insurance for medication coverage, but the heavy lifting is largely patient-driven. Prior authorization processes are typically required for Wegovy coverage and can be onerous.
For patients with strong commercial insurance covering Wegovy without restrictive PA requirements, both platforms produce similar total costs. For patients with restrictive PA requirements, the experience varies — neither platform guarantees PA approval, and both may require multiple submissions.
Some patients use the platforms to obtain a Wegovy prescription that they then transfer to a local in-network pharmacy where insurance handles the medication directly. This is permissible at both platforms.
Pharmacy delivery and supply
Both platforms coordinate Wegovy delivery through partner pharmacies. Ro operates Ro Pharmacy directly; Hims partners with affiliated pharmacies. Wegovy supply has been intermittently constrained since launch, with availability varying by dose strength.
The 2.4mg maintenance dose has historically been the most readily available; lower titration doses (0.25mg, 0.5mg, 1.0mg, 1.7mg) have been more frequently in shortage. Both platforms have experienced supply-related delays. The 2025 FDA shortage list updates affected compounded semaglutide availability, but branded Wegovy supply has stabilized.
Compounded semaglutide alternatives — largely phased out
Through 2024, both Hims and Ro offered compounded semaglutide as a cheaper alternative to branded Wegovy. The compounded options were typically priced $199-299/month at Hims and $250-450/month at Ro.
The FDA’s 2025 decisions removing semaglutide from the shortage list forced both platforms to phase out most compounded options. As of 2026, compounded semaglutide is largely unavailable through these platforms for new patients. Patients seeking lower-cost semaglutide alternatives now typically need to look at branded Wegovy with savings programs, switch to a different medication class, or work with a compounding pharmacy directly under specific clinical scenarios.
The Ozempic question
Some patients ask about Ozempic specifically rather than Wegovy. Ozempic is the same medication (semaglutide) at different dose strengths, FDA-approved for type 2 diabetes rather than weight loss specifically. Off-label Ozempic prescribing for weight loss is technically possible but increasingly uncommon as Wegovy has become FDA-approved and insurance coverage has shifted.
Neither Hims nor Ro typically prescribes off-label Ozempic for weight loss in 2026. For patients with type 2 diabetes plus obesity, Ozempic prescribed for the diabetes indication may produce weight loss as a beneficial side effect, but this is generally handled through primary care or endocrinology rather than DTC weight loss platforms.
Specific use cases — when each platform wins
Choose Hims if: Promotional pricing at signup is favorable. You’re already using Hims for other men’s or women’s health needs (the Hers brand uses the same infrastructure for women). You want the slightly lower visit fee ($79 vs $99).
Choose Ro if: You prefer the cleaner program structure with $145 monthly membership clearly defined. You’re already using Ro for other men’s health needs. The slightly more refined clinical experience matters to you.
Choose neither if: You have strong insurance coverage for Wegovy and want to handle the prescription through a primary care doctor or in-person bariatric medicine. The platform fee is unnecessary if insurance handles the medication directly.
Frequently Asked Questions
Is Wegovy through Hims the same as through Ro?
Yes. Both platforms dispense the same branded Wegovy from Novo Nordisk. The medication is identical regardless of which platform writes the prescription.
Why is Wegovy so expensive?
Novo Nordisk sets Wegovy’s list price at approximately $1,349/month (28-day supply). The pricing reflects the medication’s clinical efficacy and the manufacturer’s market positioning. Insurance, savings programs, and patient assistance can reduce out-of-pocket cost for eligible patients.
Can I get cheaper Wegovy through Hims or Ro?
The medication price is set by Novo Nordisk and similar at both platforms. Neither platform substantially discounts branded Wegovy. The difference between platforms is primarily in program fees, not medication cost.
Do both platforms accept Wegovy insurance prior authorization?
Both can coordinate PA submissions but neither guarantees approval. PA processes are insurer-driven and can be onerous regardless of which platform handles the prescription.
Are there cheaper Wegovy alternatives through these platforms?
Compounded semaglutide alternatives have largely been phased out. Both platforms also offer Zepbound (tirzepatide) which has similar efficacy and similar pricing. Patients seeking lower-cost weight loss medications may need to consider non-GLP-1 options through platforms like Found.
The bottom line on Wegovy through Hims vs Ro
For Wegovy specifically, Hims and Ro are largely interchangeable. The medication is the same (Novo Nordisk’s branded Wegovy at manufacturer pricing). Program fees differ slightly with Hims having a lower visit fee and Ro having a clearer monthly membership structure. Insurance navigation, eligibility screening, and pharmacy delivery are broadly similar. Choose based on which platform’s promotional pricing fits your situation, which you’re already using for other needs, and personal preference around clinical experience. For patients with strong insurance coverage, working directly with a primary care doctor or bariatric medicine specialist may eliminate the need for either platform’s program fee.